Anti-HVEM Antibody Promoting LIGHT Binding for Solid Tumors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-HVEM antibodies either inhibit the binding of HVEM to BTLA and gD without promoting its binding to LIGHT, or they do not specifically target cancer treatments effectively.
Innovation Solution
Development of an anti-HVEM monoclonal antibody that binds to human HVEM with high affinity, inhibiting the binding to BTLA and gD while promoting the binding to LIGHT, along with a method for producing and administering this antibody for cancer treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If an anti-HVEM antibody is designed to inhibit the binding of HVEM to BTLA and gD, then the antibody shows promise for treating hematologic malignancies and autoimmune diseases, but it fails to promote the binding of HVEM to LIGHT, limiting its effectiveness for solid tumor treatment
Solution Approach 1:
The antibody is designed to exhibit different functional effects at different binding interfaces: it inhibits HVEM-BTLA binding while simultaneously promoting HVEM-LIGHT binding. This local differentiation of binding effects allows the single antibody to address multiple disease types with different pathogenic mechanisms
Solution Approach 2:
The anti-HVEM antibody achieves multi-functionality by simultaneously performing two opposing actions: blocking inhibitory HVEM-BTLA interactions and enhancing stimulatory HVEM-LIGHT interactions. This dual functionality enables the antibody to treat both hematologic malignancies and solid tumors effectively
2Reliability
If existing anti-HVEM antibodies block all binding interactions of HVEM including LIGHT, then they show broad inhibition activity, but they cannot selectively promote anti-tumor immune responses through HVEM-LIGHT signaling
Solution Approach 1:
The antibody exhibits selective functional outcomes for different HVEM ligands: it blocks BTLA and gD binding while promoting LIGHT binding. This local quality differentiation at molecular interfaces enables selective enhancement of desired anti-tumor signaling pathways without interfering with other immune regulation mechanisms
Solution Approach 2:
The antibody acts as an intermediary that modulates different HVEM-ligand interactions in opposite directions. By serving as a selective mediator, it enhances beneficial HVEM-LIGHT signaling while blocking harmful HVEM-BTLA interactions, achieving precise control over immune response regulation
Data Source
AI summary
Provided are an anti-HVEM monoclonal antibody that binds to human HVEM with high affinity, and inhibits the binding of HVEM to BTLA but promotes the binding of HVEM to LIGHT, and thus can be used alone or in combination with other therapeutic agents to treat solid tumor or hematologic malignancy, and a composition and a method which are related to the antibody.